Soumitra S Ghosh

This inventor holds 59 USPTO granted patents and 18 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in Polypeptide Engineering (CPC class C07K). Top assignees: Amylin Pharmaceuticals, Inc., Astrazeneca Pharmaceuticals LP, Mitokor, Inc.. Active years: 1988-2026.

USPTO Granted Patents = 59 (Patent Applications = 18)

% Patents Active = 49.2

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 11 (Patent Applications = 28)

Average Co-Inventor Count = 4.4

ph-index = 16

Forward Citations = 1,124(Granted Patents)

Forward Citations (Not Self Cited) = 1,088(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Wilmington, DE (US) (2015)
San Diego, CA (US) (1988 - 2023)

Company Filing History:

21 out of 164

Amylin Pharmaceuticals, Inc.

patents

15 out of 39

Astrazeneca Pharmaceuticals LP

Siska Diagnostics, Inc.

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

8. 1 out of 4

Aegerion Pharmaceuticals, Inc.

patents

9. 1 out of 3

Amryt Pharmaceuticals Inc.

patents

10. 1 out of 1

PEP2TANGO Therapeutics Inc.

Smithkline Beecham Corporation

patents

13. 1 out of 16,008

University of California

patents

14. 1 out of 1,220

Vanderbilt University

patents

15. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1988-2026

Loading Chart...

Areas of Expertise:

Polypeptide

Peptides

Diabetes Treatment

Hybrid Polypeptides

GLP-1 Agonist

Amylin Peptides

Mitochondrial Function

Adenine Nucleotide Translocator

Inhibitor Conjugates

Insulin Secretion

Cobalt-Porphyrin

Immunogenicity Reduction

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735457 - COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE (2026-09-15),

2. 11827690 - ApoC-II mimetic peptides (2023-11-28),

3. 11535659 - Engineered polypeptides having enhanced duration of action (2022-12-27),

4. 11357829 - Systems, compositions and methods for treating diabetes (2022-06-14),

5. 11136372 - ApoC-II mimetic peptides (2021-10-05),

6. 9879063 - Engineered polypeptides having enhanced duration of action and reduced immunogenicity (2018-01-30),

7. 9593154 - Engineered polypeptides having enhanced duration of action (2017-03-14),

8. 9453063 - Hybrid polypeptides with selectable properties (2016-09-27),

9. 9382304 - Engineered polypeptides having enhanced duration of action with reduced immunogenicity (2016-07-05),

10. 9249181 - C-terminal amidation of polypeptides (2016-02-02),

11. 9217022 - GLP-1 receptor agonist compounds having stabilized regions (2015-12-22),

12. 9133260 - GIP analog and hybrid polypeptides with selectable properties (2015-09-15),

13. 8906849 - Pancreatic polypeptide family motifs, polypeptides and methods comprising the same (2014-12-09),

14. 8895498 - GIP and exendin hybrid polypeptides (2014-11-25),

15. 8759295 - Peptide-peptidase inhibitor conjugates and methods of using same (2014-06-24),

Of course, I'd be glad to assist with that! Here is the article about inventor Soumitra S Ghosh:

Title: The Innovative Mind of Soumitra S Ghosh

Introduction: Soumitra S Ghosh, a talented inventor based in San Diego, CA (US), has made significant contributions to the field of medical science through his numerous patented inventions.

Latest Patents: Among his impressive portfolio of 58 patents, two of his recent inventions stand out. The first patent relates to ApoC-II mimetic peptides, offering a novel approach to treating hypertriglyceridemia. The second patent focuses on engineered polypeptides with enhanced duration of action, showcasing his commitment to developing innovative pharmaceutical solutions for various diseases and disorders.

Career Highlights: Soumitra S Ghosh has honed his expertise while working with reputable companies such as Amylin Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. His groundbreaking research and inventions have paved the way for novel treatment options in areas like dyslipidemia, Alzheimer's disease, and metabolic disorders.

Collaborations: Throughout his career, Soumitra S Ghosh has collaborated with esteemed peers such as Odile Esther Levy and Robert E Davis. Together, they have fostered a culture of innovation and excellence, leading to the development of cutting-edge medical solutions.

Conclusion: Soumitra S Ghosh's relentless pursuit of innovation and his commitment to improving healthcare make him a standout figure in the world of inventors. His remarkable patents and collaborative efforts underscore his dedication to advancing medical science and improving patient outcomes.